NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Core Insights - NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol [1][3] - The company aims to address the unmet need for safe and well-tolerated LDL-lowering therapies, particularly for patients who do not respond adequately to existing treatments [3] Company Overview - NewAmsterdam Pharma is investigating obicetrapib, a low-dose, once-daily CETP inhibitor, in multiple Phase 3 trials as a potential LDL-C lowering therapy [3] - The company is also exploring the use of obicetrapib in combination with ezetimibe as an adjunct to statin therapy for patients with elevated LDL-C [3] Upcoming Events - Company management will participate in the TD Cowen 45th Annual Healthcare Conference in Boston on March 4-5, 2025, with a presentation scheduled for 1:50 p.m. ET on March 4 [4] - The company will also present at the Leerink Partners Global Healthcare Conference in Miami on March 10, 2025, at 8:00 a.m. ET [4] - Additionally, management will be available for one-on-one meetings at the Jefferies Biotech on the Beach Summit in Miami on March 12, 2025 [4]